Grid view List view

Showing all 14 results

bravoxin-10 - 50ml
POM
View product

Bravoxin 10- 50 ml

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

Target Species: cattle and sheep. Indications for use
For the active immunisation of sheep and cattle against disease associated with infections caused by Clostridium perfringens type A, C. perfringens type B, C. perfringens type C, C. perfringens type D, Clostridium chauvoei, Clostridium novyi type B, Clostridium septicum, Clostridium sordellii and Clostridium haemolyticum and against tetanus caused by Clostridium tetani.
For the passive immunisation of lambs and calves against infections caused by the above mentioned clostridial species (except C. haemolyticum in sheep).

More information can be found on the following link: www.noahcompendium.co.uk/Bravoxin10

Cylap H.V.D.
POM
View product

Cylap VHD Rabbit

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

Cylap vaccine is an adjuvanted vaccine containing inactivated viral haemorrhagic disease (VHD) virus, for active immunisation to prevent clinical signs and mortality caused by rabbit viral haemorrhagic disease.

  • 1 mL initial vaccination dose by subcutaneous route.
  • Rabbits should be vaccinated at 10-12 weeks of age.
  • An annual booster vaccination is recommended.
Filavac
POM
View product

FILAVAC VHD K C+V Rabbit

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

 

For active immunisation of rabbits (fattening and future breeders) from 10 weeks of age, to reduce mortality due to rabbit haemorrhagic disease caused by classical (RHDV1) and type 2 (RHDV2) virus strains.

Onset of immunity: 7 days.
Duration of immunity: 12 months.

One dose per subcutaneous injection to each animal with a volume of 0.5 ml for the single-dose presentation.

First vaccination from the 10th week of age.
Re-vaccination: annual

POM
View product

LetiFend®: vaccine against canine leishmaniasis

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.
Indications for use, specifying the target species

LetiFend®: vaccine against canine leishmaniasis

Safety : Excellent tolerability shown in a wide range of breeds and ages.

Convenience: A single annual dose confers immunity for 365 days.

Reliability: Specific immune response to vaccination that does not interfere with the serological diagnosis of the disease.
LetiFend® reduces the risk of developing clinical leishmaniasis

A dog vaccinated with LetiFend® presents:

 

LetiFend® benefits

More information can be found on the following link: www.noahcompendium.co.uk/Letifend

Nobivac DHPPi
POM
View product

Nobivac DHPPi Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

 

Nobivac DHPPi is a core vaccine that contains live attenuated canine distemper virus, canine adenovirus (CAV-2), canine parvovirus (C154) and canine parainfluenza virus.

Core Canine Vaccination
Vaccination is an integral part of a preventative health care programme. Every dog should be vaccinated against 3 core diseases – canine distemper, infectious hepatitis and canine parvo virus. These diseases can have devastating consequences for a dog and it is easy to prevent them by regular vaccination.

Leading technology for premium protection
Intervet/Schering-Plough Animal Health has been a world leader in research and development of canine vaccines for over 20 years. In 1987, the first “high titre, low passage” vaccine against parvovirus – Nobivac ParvoC – was launched containing a patented strain of parvovirus called C154. The vaccine was the first parvo vaccine able to break through levels of maternally-derived antibodies. It was a revolution in canine vaccination.

Today, the Nobivac range still provides leading technology and premium parvo protection with vaccines that now provide proven protection against all known types of canine parvovirus (including types 2a, 2b and 2c), protection in puppies from as early as 10 weeks of age, and the convenience of single vaccination in dogs with unknown vaccination histories.

 

Nobivac KC
POM
View product

Nobivac KC Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal. 

 

A live attenuated freeze-dried vaccine containing Bordetella bronchiseptica and canine parainfluenza virus.

Indications
For the active immunisation of dogs against B. bronchiseptica and canine parainfluenza virus, aiding in the protection against canine cough.

  • Immunity is achieved as early as 72 hours after vaccination for B. bronchiseptica and 3 weeks for canine parainfluenza.
  • The components of Nobivac KC have been shown to protect against canine kennel cough caused by B. bronchiseptica and parainfluenza virus for at least 12 months.
  • Nobivac KC can be used in pregnant bitches.
  • Nobivac KC is safe for use in pups from 2 weeks of age.

Dosage
Reconstitute each single dose vial with one vial (0.4ml) of Nobivac KC diluent. Administer entire contents into a single nostril only.

Nobivac Lepto 2
POM
View product

Nobivac Lepto2 Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

A bivalent, inactivated vaccine for the immunization of dogs against leptospirosis caused by Leptospira canicola and Leptospira icterohaemorrhagiae.

Composition
Each dose of inactivated vaccine contains
Leptospira interrogans serotype Canicola strain Ca-12-000 at least 957 units/ml
Icterohaemorrhagiae strain 820k at least 625 units/ml

Indications
Active immunisation against Leptospirosis caused by Leptospira icterohaemorrhagiae and Leptospira canicola of Leptospira interrogans. Animals are protected against clinical disease, and against becoming renal carriers after challenge.

Dosage and Administration
Inject 1ml of Nobivac Lepto subcutaneously. Nobivac Lepto can also be used to reconstitute Intervet’s freeze dried vaccines, Nobivac Puppy DP and Nobivac DHPPi.

Vaccination Programme
Nobivac Lepto is indicated for a basic vaccination schedule with a first vaccination at the age of 8 – 9 weeks of age, followed by a booster at 12 weeks of age, and for annual revaccination.
Vaccination with Nobivac Lepto, however is part of a comprehensive vaccination programme.

Nobivac Myxo-RHD
POM
View product

Nobivac Myxo-RHD Rabbit

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

Indications for use
For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease (RHD) caused by classical RHD virus strains.
Onset of immunity: 3 weeks.
Duration of immunity: 1 year.
Use during pregnancy, lactation or lay
Pregnancy:
Studies involving the use of the vaccine during early pregnancy were inconclusive, therefore vaccination is not recommended during the first 14 days of pregnancy.
Fertility:
No safety study on the reproductive performance has been conducted in male rabbits (bucks). Therefore, the vaccination of breeding bucks is not recommended.
After reconstitution, administer 1 dose of vaccine by subcutaneous injection to rabbits from 5 weeks of age onwards.
Revaccinate annually.
Nobivac Rabies Cat and Dog
POM
View product

Nobivac Rabies Cat&Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.
Indications for use, specifying the target species
For the active immunisation against rabies to reduce clinical signs and mortality.
Onset of immunity: an adequate serological response (≥ 0.5 I.U.) has been demonstrated 2 to 3 weeks after vaccination.
Duration of immunity: 3 years.
Contraindications
Do not use in unhealthy animals. The vaccine may not be effective in animals incubating the disease at the time of vaccination.
Primary course and booster vaccination
Dogs & cats
Primary vaccination age* 12 weeks or older
Booster vaccination every 3 years
Route of administration intramuscularly or subcutaneously
* Primary vaccination may be administered at an earlier age (minimum in dogs and cats of 4 weeks of age), but then a repeat vaccination must be given at the age of 12 weeks.
Nobivac Tricat Trio
POM
View product

Nobivac Tricat Trio Cat

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

Nobivac® Tricat Trio is a live attenuated, freeze-dried vaccine containing the 3 core viruses – feline panleucopaenia virus, feline herpesvirus, and feline calicivirus.

Core feline vaccination
Vaccination is an integral part of a preventative health care programme. Every cat should be vaccinated against 3 core diseases – feline panleucopaenia (or infectious enteritis), feline herpesvirus and feline calicivirus (both causes of “cat flu”). These diseases can have devastating consequences for a cat and it is easy to prevent them by regular vaccination.

Active Ingredients
A live attenuated freeze dried vaccine containing feline herpes virus type 1 (rhinotracheitis), feline calicivirus and feline panleucopaenia virus (MW-1).

Indications
For the active immunisation of cats against feline panleucopaenia virus (FPLV), feline herpes virus (FHV) and feline calicivirus (FCV). Vaccination will reduce clinical signs caused by infection with FHV and FCV; reduce replication of FCV, and prevent shedding of FPLV.

  • The duration of immunity is 3 years for the FCV, FHV and FPLV components, as confirmed by challenge study.

Dosage
The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by addition of one vial of Nobivac Diluent.

For an initial vaccination, two doses are required, at an interval of 3 to 4 weeks. The first inoculation is given from the age of 8-9 weeks and the second inoculation from the age of 12 weeks. If earlier vaccination if desirable or necessary, vaccination is appropriate from 6 weeks of age onwards, but should be followed by the normal vaccination scheme at 8-9 and 12 weeks of age.

Revaccination
A single dose. Recommended revaccination following initial programme:

  • FCV, FHV and FPLV revaccinate three-yearly.
  • For cats exposed to high-risk environments, annual revaccination should be considered.
ROTAVEC CORONA x 10ML (5 doses)
POM
View product

Rotavec Corona 10 ml

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

Target Species: cattle. Uses
For the active immunisation of pregnant cows and heifers to raise antibodies against E. coli adhesin F5 (K99) antigen, rotavirus and coronavirus. While calves are fed colostrum from vaccinated cows during the first two to four weeks of life, these antibodies have been demonstrated to:
– reduce the severity of diarrhoea caused by E. coli F5 (K99);
– reduce the incidence of scours caused by rotavirus;
– reduce the shedding of virus by calves infected with rotavirus or coronavirus.Onset of Immunity: Passive protection against all active substances will commence from the start of colostrum feeding.
Duration of Immunity: In calves artificially fed with pooled colostrum, protection will continue until colostrum feeding ceases. In naturally suckled calves, protection against rotavirus will persist for at least 7 days and against coronavirus for at least 14 days.

More information can be found on the following link: www.noahcompendium.co.uk/Rotavec

POM
View product

Vanguard Plus 7 Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

 

For the active immunisation of healthy puppies and dogs to prevent mortality and clinical signs due to canine distemper virus infections, to prevent clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (type 2a), to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2b and 2c), to reduce mortality and clinical signs due to canine adenovirus type 1 infections, to reduce clinical signs and infection or excretion due to canine adenovirus type 2 infections, to reduce clinical signs and infection due to Leptospira canicola and icterohaemorrhagiae, and to reduce pathological signs of disease caused by canine parainfluenzavirus infections.
Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Scheme. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age.
The duration of immunity for canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2 and the leptospiral components is at least 12 months. However, the duration of immunity for canine parainfluenzavirus has not been determined.
Basic Vaccination Scheme
Puppies younger than 10 weeks of age
Two doses of Vanguard 7 at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age.
Puppies 10 weeks of age and older

A single dose of Vanguard 7, followed by a single dose of Vanguard Lepto ci at least 14 days later.
Re-vaccination scheme
A single dose of Vanguard 7 to be given annually thereafter.

Vanguard Plus CPV
POM
View product

Vanguard Plus CPV (Parvo) Dog

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

VANGUARD Plus CPV is licensed for vaccination of healthy dogs 6 weeks of age or older as an aid in the prevention of canine parvoviral enteritis caused by canine parvovirus (CPV).  In addition, cross-protection against CPV type 2c has been demonstrated.

VANGUARD Plus CPV is a high-titer, modified-live canine parvovirus (CPV) strain attenuated by low passage on an established canine cell line. The combination of high titer and low passage gives VANGUARD Plus CPV the immunogenic properties capable of stimulating active immunity in the presence of maternal antibodies.

DIRECTIONS:

1. General Directions: Vaccination of healthy dogs is recommended. Shake well. Aseptically administer 1 mL subcutaneously or intramuscularly.

2. Primary Vaccination: Healthy dogs 6 weeks of age or older should receive 3 doses, each administered 3 weeks apart.

3. Revaccination: Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal’s lifestyle and risk of exposure.*

*American Veterinary Medical Association, Position Statements on Biologics, June 2001.

Versifel FeLV
POM
View product

Versifel FeLv Cat

Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.

 

For active immunization of susceptible cats from 9 weeks of age to reduce the number of cats infected with FeLV and presenting clinical signs of the related disease. No data are available in the studies to demonstrate protection against related clinicaldisease but prevention of infection is associated with protection against related clinical disease.
Onset of immunity occurs within four weeks of the completion of the primary vaccination course.

The duration of immunity is at least one year after the primary course and three years after the booster.

Only healthy animals should be vaccinated.
Do not vaccinate FeLV antigen positive cats.
Therefore a test for presence of FeLV before vaccination is recommended.